Literature DB >> 25824220

In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.

Ken B Waites1, Donna M Crabb2, Lynn B Duffy2, Michael D Huband3.   

Abstract

In this study, susceptibilities were determined for AZD0914, a spiropyrimidinetrione DNA gyrase inhibitor, azithromycin, doxycycline, and levofloxacin against Mycoplasma and Ureaplasma species. The activity of AZD0914 was comparable to that of levofloxacin and doxycycline against Mycoplasma genitalium and Mycoplasma pneumoniae. The AZD0914 MIC90 against Mycoplasma hominis was 8-fold greater than that for levofloxacin. The AZD0914 MIC90 against Ureaplasma species was 4-fold less than that for azithromycin and 8-fold less than that for levofloxacin and doxycycline.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25824220      PMCID： PMC4432128          DOI： 10.1128/AAC.04945-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in human Ureaplasma spp.

Authors:  Li Xiao; Donna M Crabb; Lynn B Duffy; Vanya Paralanov; John I Glass; Daniel L Hamilos; Ken B Waites
Journal:  Int J Antimicrob Agents       Date:  2011-02-24       Impact factor: 5.283

2.  High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.

Authors:  Susanne Jacobsson; Daniel Golparian; Richard A Alm; Michael Huband; John Mueller; Jorgen Skov Jensen; Makoto Ohnishi; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

3.  In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  Stephan A Kohlhoff; Michael D Huband; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

4.  In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.

Authors:  Michael D Huband; Patricia A Bradford; Linda G Otterson; Gregory S Basarab; Amy C Kutschke; Robert A Giacobbe; Sara A Patey; Richard A Alm; Michele R Johnstone; Marie E Potter; Paul F Miller; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

5.  Fluoroquinolone resistance in Ureaplasma parvum in the United States.

Authors:  Lynn Duffy; John Glass; Geraldine Hall; Robin Avery; Raymond Rackley; Scott Peterson; Ken Waites
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

6.  Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates.

Authors:  Xiao Li; T Prescott Atkinson; James Hagood; Chris Makris; Lynn B Duffy; Ken B Waites
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

7.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
  7 in total
  8 in total

Review 1.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Li Xiao; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 3.  New Horizons in Mycoplasma genitalium Treatment.

Authors:  Catriona S Bradshaw; Jorgen S Jensen; Ken B Waites
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

4.  High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.

Authors:  Magnus Unemo; Johan Ringlander; Catherine Wiggins; Hans Fredlund; Susanne Jacobsson; Michelle Cole
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

Review 5.  Management of Mycoplasma genitalium infections - can we hit a moving target?

Authors:  Jørgen Skov Jensen; Catriona Bradshaw
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

Review 6.  Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment.

Authors:  Sabine Pereyre; Julien Goret; Cécile Bébéar
Journal:  Front Microbiol       Date:  2016-06-22       Impact factor: 5.640

7.  Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.

Authors:  Pan F Chan; Velupillai Srikannathasan; Jianzhong Huang; Haifeng Cui; Andrew P Fosberry; Minghua Gu; Michael M Hann; Martin Hibbs; Paul Homes; Karen Ingraham; Jason Pizzollo; Carol Shen; Anthony J Shillings; Claus E Spitzfaden; Robert Tanner; Andrew J Theobald; Robert A Stavenger; Benjamin D Bax; Michael N Gwynn
Journal:  Nat Commun       Date:  2015-12-07       Impact factor: 14.919

Review 8.  Mycoplasma genitalium infections: current treatment options and resistance issues.

Authors:  Sunil Sethi; Kamran Zaman; Neha Jain
Journal:  Infect Drug Resist       Date:  2017-09-01       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.